Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis
Abstract Background Little is known about the prognostic difference of anti-EGFR therapy, cetuximab (CTX) or nimotuzumab (NTZ), concurrently with induction chemotherapy (IC, investigational arm) or RT (control arm) for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We condu...
Main Authors: | Hao Peng, Ling-Long Tang, Xu Liu, Lei Chen, Wen-Fei Li, Yan-Ping Mao, Yuan Zhang, Li-Zhi Liu, Li Tian, Ying Guo, Ying Sun, Jun Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4268-y |
Similar Items
-
Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
by: Zhaodong Fei, et al.
Published: (2020-10-01) -
Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
by: Jing-Feng Zong, et al.
Published: (2021-11-01) -
The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
by: Wang Zhi-Qiang, et al.
Published: (2019-11-01) -
Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
by: Wen-Fei Li, et al.
Published: (2016-11-01) -
Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)